Modality
Small Molecule
MOA
FXIai
Target
CD3
Pathway
Sphingolipid
Endometrial Ca
Development Pipeline
Preclinical
~May 2018
→ ~Aug 2019
Phase 1
~Nov 2019
→ ~Feb 2021
Phase 2
May 2021
→ Dec 2028
Phase 2Current
NCT03081841
1,246 pts·Endometrial Ca
2021-05→2028-12·Not yet recruiting
1,246 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-12-142.7y awayPh3 Readout· Endometrial Ca
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P2/3
Not yet…
Catalysts
Ph3 Readout
2028-12-14 · 2.7y away
Endometrial Ca
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03081841 | Phase 2/3 | Endometrial Ca | Not yet recr... | 1246 | HAM-D |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-6360 | Novartis | Approved | CD38 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| AZN-1715 | AstraZeneca | Phase 3 | AHR | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| SNY-4496 | Sanofi | Phase 2/3 | CD3 | |
| NVO-9630 | Novo Nordisk | Phase 2 | CD3 | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| Miriglumide | Alnylam | Phase 3 | CD3 | |
| Semazasiran | BeiGene | Phase 1 | PD-1 |